查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1972592

β-地中海型贫血检测市场：按检测类型、技术、检体类型、最终用户和分销管道划分 - 全球预测（2026-2032年）

Beta Thalassemia Testing Market by Test Type, Technology, Sample Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，β-地中海贫血检测市场价值将达到 5.2161 亿美元，到 2026 年将成长至 5.7225 亿美元，到 2032 年将达到 9.7102 亿美元，复合年增长率为 9.28%。

主要市场统计数据
基准年 2025 5.2161亿美元
预计年份：2026年 5.7225亿美元
预测年份 2032 971,020,000 美元
复合年增长率 (%) 9.28%

全面概述β地中海贫血检测的进展、临床必要性以及影响诊断和治疗路径的相关人员的优先事项。

β-地中海型贫血检测如今在遗传医学、公共卫生和临床诊断的交叉领域发挥着至关重要的作用。分子技术的进步，以及新生儿和产前筛检计画的不断扩展，使得该疾病从一种诊断异常转变为可透过协调的检测途径进行有效管理的疾病。本节概述了推动检测需求的临床需求、将诊断整合到诊疗路径中的实际操作情况，以及检查室管理人员、临床负责人和公共卫生官员的策略重点。

一场变革性的转变正在透过创新、政策影响以及不断变化的临床和消费者期望，重新定义β-地中海贫血检测的格局。

β-地中海型贫血的检测领域正经历着变革性的转变，这主要得益于创新、法规的不断改进以及医疗模式的转变。次世代定序和基于CRISPR的检测等分子技术正在提高诊断分辨率，实现更精准的基因分型，并有助于制定标靶治疗方案。同时，包括高效液相层析和毛细管电泳在内的传统检测平台也不断改进，进而提升筛检项目的通量和分析精度。

2025 年美国加征关税对 β-地中海贫血检测的供应链、采购趋势和临床服务提供的累积影响。

美国加征关税和2025年贸易政策变化对β-地中海贫血检测生态系统产生了累积的营运和策略影响。特种试剂、诊断设备和耗材的供应链变得更加复杂，迫使许多供应商和製造商调整筹资策略。为此，采购部门正在加快供应商多元化，并加强与国内製造商的对话，以确保检测服务的连续性。

关键細項分析，以确定测试类型、技术、最终用户、通路和检体类型交叉并影响临床路径的领域。

基于细分市场的分析揭示了不同检测类型、技术、终端用户、通路和检体类型之间存在的细微差异，并揭示了不同的市场机会和营运需求。按检测类型划分，市场涵盖带因者筛检、诊断检测、新生儿筛检、就地检验和产前筛检。每个管道都有其独特的营运需求，例如新生儿筛检所需的高通量集中式工作流程，以及产前检测和照护现场中对快速结果交付的需求。从技术面来看，诊断平台包括毛细管电泳、基于 CRISPR 的检测、高效液相层析、微阵列分析、次世代定序和聚合酵素链锁反应(PCR)。这些技术在解析度、仪器复杂性和实验室面积方面存在差异，其应用受到临床目标和资源可用性的影响。

区域趋势和采用模式影响美洲、欧洲、中东和非洲以及亚太地区获得β地中海贫血诊断服务的途径。

区域趋势对β-地中海贫血检测的部署模式、监管协调和营运模式有显着影响。在美洲，完善的新生儿筛检基础设施和一体化的检查室网络为可扩展的项目提供了支持，但遍远地区和不同支付方的可及性差异使得必须采取有针对性的干预措施来覆盖服务不足的人群。在欧洲、中东和非洲，不同的管理体制和侦测能力水准造成了部署曲线的复杂性。集中式标准实验室和新兴的照护现场倡议并存，跨国合作对于协调标准和培训专案至关重要。在亚太地区，对基因组分析能力的快速投资以及对产前和新生儿筛检日益增长的关注正在推动部署速度的加快，但对偏远地区人群的后勤支援和检体运输网路的差异仍然是营运方面需要关注的问题。

企业间竞争、策略联盟、技术授权和商业化方法影响β-地中海贫血检测的竞争格局。

β-地中海型贫血检测领域的竞争格局呈现出多元化的特点，既有成熟的诊断设备製造商，也有创新分子技术开发公司和专业服务供应商。设备製造商和试剂供应商致力于提升检测灵敏度和易用性，而分子技术Start-Ups则专注于小型化、可重复检测以及将检测与临床决策支援工具整合。合约实验室和联网诊断中心则透过提供检验的工作流程和外部品质评估服务来拓展服务范围，为小规模诊所和血库提供必要的支援。

为製造商、临床领导者、支付者和政策制定者提供实用建议，以加快可靠的检测途径并改善患者预后。

产业领导者应采取果断行动，提升检测的可靠性、患者可及性和营运韧性。首先，透过多元化供应来源，优先与拥有清晰的连续性计划和检验的品质系统的製造商建立合作关係，降低地缘政治和关税相关风险。其次，透过投资灵活的检测平台，使检测方法适应临床需求，这些平台既能满足新生儿筛检的集中式高通量处理需求，也能满足以地区为基础筛检的分散式照护现场需求。第三，积极与支付方和监管机构合作，建立能够认可早期检测和遗传咨询临床价值的报销框架和核准流程。

本文檔概述了严谨的调查方法，解释了β-地中海型贫血检测分析的资料来源、分析方法、检验程序和限制。

本分析整合了第一手访谈、二手文献综述和结构化检验，以确保分析的严谨性。第一手研究包括与实验室主任、临床遗传学家、检体采集专家和监管顾问的咨询，以了解实际操作和策略重点。二级资讯来源包括同行评审出版物、专业学会指南和公开的监管文件，以梳理证据基础并为技术性能提供背景资讯。研究结果透过跨资讯来源的三角验证进行比对，以识别趋同趋势并突出需要进一步研究的不确定领域。

简明扼要的结论，整合了策略意义、营运重点和未来行动，供参与β-地中海贫血检测和治疗的相关人员参考。

总之，由于技术创新、医疗模式的演变以及对供应链韧性的日益重视，β-地中海贫血检测正处于转折点。高解析度分子检测、不断扩大的新生儿和产前筛检专案以及分散式检查方案的整合，为改善早期发现和患者管理创造了机会。然而，从检体物流和检查室间互通性到采购流程的复杂性等一系列营运挑战，仍然是专案成功的关键。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 β-地中海贫血检测市场（依检测类型划分）

  • 携带者筛检
  • 诊断测试
  • 新生儿筛检
  • 即时检测
  • 产前筛检

第九章 β-地中海贫血检测市场：依技术划分

  • 毛细管电泳
  • 基于 CRISPR 的检测
  • 高效液相层析
  • 微阵列分析
  • 次世代定序
  • 聚合酵素链锁反应

第十章：依检体类型分類的β-地中海贫血检测市场

  • 羊水
  • 血液样本
  • 干血斑

第十一章 β-地中海贫血检测市场：依最终用户划分

  • 血库
  • 诊断中心
  • 家庭医疗保健服务
  • 医院
  • 专科诊所

第十二章 β-地中海型贫血检测市场：依通路划分

  • 电子商务平台
  • 医院收购
  • 线上管道
  • 药房和零售

第十三章 β-地中海型贫血检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 β-地中海型贫血检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 β-地中海型贫血检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国β-地中海贫血检测市场

第十七章：中国β-地中海贫血检测市场

第十八章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • A. Menarini Diagnostics srl
  • Abbott Laboratories
  • BGI Genomics Co. Ltd.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guangdong Hybribio Limited Corporation
  • Illumina Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Natera Inc.
  • PerkinElmer Inc.
  • QIAGEN NV
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
Product Code: MRR-9A6A6F297442

The Beta Thalassemia Testing Market was valued at USD 521.61 million in 2025 and is projected to grow to USD 572.25 million in 2026, with a CAGR of 9.28%, reaching USD 971.02 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 521.61 million
Estimated Year [2026] USD 572.25 million
Forecast Year [2032] USD 971.02 million
CAGR (%) 9.28%

Comprehensive overview of beta thalassemia testing advances, clinical imperatives, and stakeholder priorities shaping diagnostics and care pathways

Beta thalassemia testing now occupies a pivotal role at the intersection of genetic medicine, public health, and clinical diagnostics. Advances in molecular methods, combined with expanding newborn and prenatal screening programs, have shifted the condition from a diagnostic curiosity to a disease managed through coordinated testing pathways. This section frames the clinical imperatives that drive testing demand, the operational realities of integrating diagnostics into care pathways, and the strategic priorities for laboratory managers, clinical leaders, and public health officials.

Clinicians require timely, accurate information to advise families, manage transfusion strategies, and evaluate candidates for curative therapies. Parallel to these clinical needs, laboratory networks are adapting workflows to accommodate a wider array of test types that span carrier screening, prenatal assessment, and newborn detection. Across these junctures, supply chain resilience, sample integrity, and interoperability of laboratory information systems are emerging as core determinants of reliable service delivery. The introduction of novel testing modalities is redefining what constitutes standard of care and is compelling stakeholders to rethink procurement, accreditation, and quality assurance practices.

Transformative shifts redefining the beta thalassemia testing landscape through innovation, policy influence, and evolving clinical and consumer expectations

The landscape for beta thalassemia testing is experiencing transformative shifts driven by innovation, regulatory evolution, and changing care models. Molecular technologies such as next-generation sequencing and CRISPR-based assays are expanding diagnostic resolution, enabling more precise genotyping and facilitating targeted therapeutic decisions. At the same time, improvements in conventional platforms-including high-performance liquid chromatography and capillary electrophoresis-are enhancing throughput and analytical precision for screening programs.

Concurrently, testing is moving closer to the point of care. Point-of-care testing solutions and dried blood spot sample workflows are enabling community-level screening and extending access into decentralized settings. This trend is paralleled by growing integration between diagnostic providers and electronic health ecosystems, which enhances result delivery and supports longitudinal patient management. Policy and payer environments are adapting, with reimbursement frameworks evolving to recognize the value of early detection and genetic counseling. Taken together, these shifts are prompting diagnostic laboratories, manufacturers, and health systems to prioritize agility, data integration, and cross-sector collaboration to capture clinical and population health benefits.

Cumulative effects of United States tariffs in 2025 on beta thalassemia testing supply chains, procurement dynamics, and clinical service delivery considerations

The imposition of tariffs and trade policy changes originating in the United States during 2025 has produced a cumulative set of operational and strategic effects on the beta thalassemia testing ecosystem. Supply chains for specialized reagents, diagnostic instruments, and consumables have experienced increased complexity, prompting many providers and manufacturers to reassess their sourcing strategies. In response, procurement teams have accelerated supplier diversification and intensified dialogue with domestic manufacturers to maintain continuity of testing services.

These dynamics have also altered procurement timing and capital planning. Clinical laboratories and health systems are extending inventory planning horizons and coordinating group purchasing efforts to mitigate exposure to tariff-driven cost variability. In addition, the tariffs have stimulated regional manufacturing conversations, encouraging investments in onshore or nearshore production of critical reagents and assay components. For research and development activities, the policy environment has emphasized the need for flexible design controls and modular supply chains that can tolerate episodic cross-border disruptions. Collectively, these adjustments affect testing availability timelines, contract negotiations, and strategic partnerships across manufacturers, distributors, and clinical laboratories.

Key segmentation insights revealing where test types, technologies, end users, distribution channels, and sample types intersect to influence clinical pathways

Segmentation-driven insight reveals nuanced opportunities and operational imperatives across test types, technologies, end users, distribution channels, and sample types. Based on Test Type, the market encompasses carrier screening, diagnostic testing, newborn screening, point-of-care testing, and prenatal screening; each pathway carries distinct operational requirements, from high-throughput centralized workflows for newborn screening to rapid turnaround needs for prenatal and point-of-care contexts. Based on Technology, diagnostic platforms include capillary electrophoresis, CRISPR-based testing, high-performance liquid chromatography, microarray analysis, next-generation sequencing, and polymerase chain reaction; these technologies vary in resolution, instrumentation complexity, and laboratory footprint, and their adoption is shaped by clinical objectives and resource availability.

Based on End User, key stakeholders range from blood banks to diagnostic centers, home healthcare services, hospitals, and specialty clinics; each end user imposes different volume, staffing, and quality control expectations, affecting how tests are validated and deployed. Based on Distribution Channel, procurement and access routes span e-commerce platforms, hospital purchases, online channels, and pharmacy & retail outlets; channel choice influences inventory management, lead times, and patient-facing access. Finally, based on Sample Type, testing methods are applied to amniotic fluid, blood sample, and dried blood spot matrices, each of which drives pre-analytic handling, transport logistics, and analytical constraints. Integrating these segmentation layers highlights that successful deployment requires alignment between technological capability, clinical workflows, and distribution strategies to ensure accuracy, accessibility, and sustainability.

Regional dynamics and adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping access to beta thalassemia diagnostic services

Regional dynamics materially influence adoption patterns, regulatory alignment, and the operational models required to deliver beta thalassemia testing. In the Americas, established newborn screening infrastructure and consolidated laboratory networks support scalable programs, yet disparities in rural access and payer heterogeneity necessitate targeted interventions to reach underserved populations. In Europe, Middle East & Africa, diverse regulatory regimes and variable laboratory capacities create a mosaic of adoption curves; centralized reference laboratories coexist with nascent point-of-care initiatives, and cross-border collaborations are essential to harmonize standards and training programs. In Asia-Pacific, rapid investment in genomic capabilities and a rising emphasis on prenatal and newborn screening are driving accelerated adoption, though logistics for remote populations and variable sample transport networks remain an operational focus.

Across these regions, technology transfer, workforce development, and tailored reimbursement models are central levers for increasing testing reliability and reach. Differences in population genetics and screening priorities also require region-specific assay validation and counseling resources. Consequently, stakeholders must design implementation plans that reflect regional regulatory pathways, laboratory capacity, and health system financing mechanisms to translate diagnostic advances into measurable improvements in patient care and public health outcomes.

Competitive company dynamics, strategic collaborations, technology licensing, and commercialization approaches influencing the beta thalassemia testing competitive landscape

Competitive company dynamics in the beta thalassemia testing space are characterized by a mix of established diagnostic manufacturers, innovative molecular technology developers, and specialized service providers. Instrument makers and reagent suppliers invest in improving assay sensitivity and ease of use, while molecular startups focus on assay miniaturization, multiplexing, and integration with clinical decision support tools. Contract laboratories and networked diagnostic centers extend reach by offering validated workflows and external quality assessment services that smaller clinics and blood banks may rely upon.

Strategic collaborations and licensing partnerships are common, as hardware providers seek to embed proprietary consumables while software vendors supply analytics and data integration layers. Commercialization approaches emphasize modular solutions that can be scaled from centralized high-throughput labs to decentralized point-of-care deployments. Meanwhile, quality assurance, accreditation, and post-market surveillance capabilities differentiate organizations that can support regulated screening programs from those focused on research or niche clinical services. For buyers and partners, evaluating vendor roadmaps, supply chain resilience, and support ecosystems is critical when selecting partners for long-term diagnostic programs.

Actionable recommendations for manufacturers, clinical leaders, payers, and policymakers to accelerate reliable testing pathways and improve patient outcomes

Industry leaders should take decisive actions to strengthen testing reliability, patient access, and operational resilience. First, diversify supply sources and prioritize partnerships with manufacturers that have clear continuity plans and validated quality systems to mitigate geopolitical and tariff-related risks. Second, invest in flexible testing platforms that enable both centralized high-throughput processing for newborn screening and decentralized point-of-care solutions for community-based screening, thereby matching test modality to clinical need. Third, engage proactively with payers and regulators to develop reimbursement frameworks and approval pathways that recognize the clinical value of early detection and genetic counseling.

In addition, enhance laboratory interoperability by adopting common data standards and integrating diagnostic outputs into electronic health records, which supports care coordination and longitudinal outcome tracking. Prioritize workforce training and accreditation programs to ensure that end users-ranging from blood banks to specialty clinics-can maintain quality across different sample types, including amniotic fluid, venous blood, and dried blood spots. Finally, pursue collaborative research and public-private initiatives to validate novel technologies in real-world settings and to scale successful protocols across regions, thereby converting innovation into sustainable clinical impact.

Rigorous research methodology explaining data sources, analytical approaches, validation steps, and limitations informing this beta thalassemia testing analysis

This analysis synthesizes primary interviews, secondary literature review, and structured validation to ensure analytical rigor. Primary research included consultations with laboratory directors, clinical geneticists, procurement specialists, and regulatory advisors to capture operational realities and strategic priorities. Secondary sources encompassed peer-reviewed publications, guidelines from professional societies, and publicly available regulatory documentation to map the evidence base and contextualize technology performance. Findings were triangulated across sources to identify convergent trends and to flag areas of uncertainty requiring further investigation.

Analytical steps included mapping diagnostic pathways against segmentation dimensions, assessing supply chain vulnerabilities, and evaluating adoption enablers across regions. Quality assurance measures comprised peer review by domain experts, cross-validation of technical assertions, and sensitivity checks for qualitative judgments. Limitations are acknowledged: the study emphasizes structural and operational analysis rather than quantitative market estimations, and evolving policy landscapes may shift practical implications. Where appropriate, the report identifies topics that warrant ongoing monitoring and potential follow-up studies to maintain relevance as technologies and regulations evolve.

Concise conclusion synthesizing strategic implications, operational priorities, and next steps for stakeholders engaged in beta thalassemia testing and care

In summary, beta thalassemia testing is at an inflection point driven by technological innovation, evolving care models, and heightened attention to supply chain resilience. The convergence of high-resolution molecular assays, expanded newborn and prenatal screening programs, and decentralized testing options is creating opportunities to improve early detection and patient management. Nonetheless, operational challenges-ranging from sample logistics and laboratory interoperability to procurement complexity-remain critical determinants of program success.

Stakeholders should prioritize integrated strategies that align technology selection with end-user capabilities, regional regulatory contexts, and distribution channels. By focusing on quality assurance, workforce development, and resilient procurement practices, health systems can translate diagnostic advances into meaningful clinical and public health outcomes. The analysis underscores the importance of cross-sector collaboration and adaptive planning to ensure that innovations in testing equitably benefit patients and health systems across diverse geographic and operational settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Beta Thalassemia Testing Market, by Test Type

  • 8.1. Carrier Screening
  • 8.2. Diagnostic Testing
  • 8.3. Newborn Screening
  • 8.4. Point-Of-Care Testing
  • 8.5. Prenatal Screening

9. Beta Thalassemia Testing Market, by Technology

  • 9.1. Capillary Electrophoresis
  • 9.2. CRISPR-Based Testing
  • 9.3. High-Performance Liquid Chromatography
  • 9.4. Microarray Analysis
  • 9.5. Next-Generation Sequencing
  • 9.6. Polymerase Chain Reaction

10. Beta Thalassemia Testing Market, by Sample Type

  • 10.1. Amniotic Fluid
  • 10.2. Blood Sample
  • 10.3. Dried Blood Spot

11. Beta Thalassemia Testing Market, by End User

  • 11.1. Blood Banks
  • 11.2. Diagnostic Centers
  • 11.3. Home Healthcare Services
  • 11.4. Hospitals
  • 11.5. Specialty Clinics

12. Beta Thalassemia Testing Market, by Distribution Channel

  • 12.1. E-Commerce Platforms
  • 12.2. Hospital Purchases
  • 12.3. Online Channels
  • 12.4. Pharmacy & Retail

13. Beta Thalassemia Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Beta Thalassemia Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Beta Thalassemia Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Beta Thalassemia Testing Market

17. China Beta Thalassemia Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. A. Menarini Diagnostics s.r.l.
  • 18.6. Abbott Laboratories
  • 18.7. BGI Genomics Co. Ltd.
  • 18.8. Bio-Rad Laboratories Inc.
  • 18.9. F. Hoffmann-La Roche Ltd.
  • 18.10. Guangdong Hybribio Limited Corporation
  • 18.11. Illumina Inc.
  • 18.12. Mylab Discovery Solutions Pvt. Ltd.
  • 18.13. Natera Inc.
  • 18.14. PerkinElmer Inc.
  • 18.15. QIAGEN N.V.
  • 18.16. Sysmex Corporation
  • 18.17. Thermo Fisher Scientific Inc.
  • 18.18. Tosoh Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CRISPR-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CRISPR-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CRISPR-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY AMNIOTIC FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY AMNIOTIC FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY AMNIOTIC FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITAL PURCHASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITAL PURCHASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITAL PURCHASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PHARMACY & RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PHARMACY & RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PHARMACY & RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)